TRENTON, N.J. & WAYNE, Pa.--(EON: Enhanced Online News)--The barriers to innovation in the life sciences – and potential solutions – will be examined by Michael Rosenblatt, M.D., executive vice president and chief medical officer at Merck in a luncheon keynote address on October 24 at Biotech 2011.
“The Barriers to Life Science Innovation: Don’t Think Biotech is Immune”
The premier bioscience conference in the mid-Atlantic region, Biotech 2011 is the eleventh joint symposium held by BioNJ and Pennsylvania Bio. On October 24-25, top leaders in the bioscience, finance and academic communities from the region and around the world will be at the Pennsylvania Convention Center in Philadelphia to network, connect with potential partners, share business strategies, and learn from their peers though a series of cutting-edge forums and panels.
In his presentation, “The Barriers to Life Science Innovation: Don’t Think Biotech is Immune,” Dr. Rosenblatt will discuss the future of innovation in the life sciences.
“There’s no denying that we are in a challenging period of innovation for new drugs. The biopharma industry’s R&D spend grew by 150 percent from 1998 to 2008, while the number of new molecular entities and biologics introduced fell by 35 percent,” said Dr. Rosenblatt.
“Some blame industry itself for this decline, some say the whole system isn’t working. Whatever the reasons, it would be a mistake to think that any of us are immune to these forces, or that the problem can be solved without all of us working together,” he continued.
With a diverse and accomplished background as a scientist, educator, hospital and global healthcare company executive, Dr. Rosenblatt currently serves as executive vice president and chief medical officer at Merck. In this role, he represents the voice of the patient inside Merck and serves as the company’s primary external advocate on medical issues.
Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School; and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology.
Prior to these leadership positions, he was senior vice president for research at Merck. Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.
Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies and is a scientific founder of ProScript, Radius Pharmaceuticals, and Theracrine.
Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.
He received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
About Janssen Biotech, Inc.
Janssen Biotech, Inc. redefines the standard of care in immunology, oncology, urology and nephrology. Built upon a rich legacy of innovative firsts, Janssen Biotech has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Beyond its innovative medicines, Janssen Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and health care professionals have access to the latest treatment information, support services and quality care. For more information on Janssen Biotech, Inc. or its products, visit www.janssenbiotech.com.
Janssen Biotech is one of the Janssen Pharmaceutical Companies of Johnson & Johnson dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to people throughout the world. Follow us on Twitter at www.twitter.com/JanssenUS.
About Biotech 2011
Designed to advance the bioiscience industries in the mid-Atlantic region, the Biotech symposium each year attracts top executives from the region's global pharmaceutical, biotechnology, medical device, and diagnostic companies; venture capitalists and other investors; university researchers; university-industry liaison officers; government officials; and support organizations. This must-attend event will feature thought-provoking panel discussions, dynamic plenary sessions, renowned keynote speakers, an Innovation Forum, an Exhibit Hall, and much more.
For more information, please go to www.Biotech2011.org.